AstraZeneca’s Phase III Provent trial results showed a statistically significant 77 percent decrease in a patient’s likelihood of developing symptomatic COVID-19 when proactively treated with Evusheld. Additionally, results were announced by Clover Biopharmaceuticals for the Phase II/III Spectra global study investigating the efficacy of the SCB-2019 (CpG 1018/Alum) vaccine booster in patients that have previously developed a COVID-19 infection.
Medicago’s COVID-19 vaccine – approved during February in Canada – is facing limited growth in the near term after the World Health Organization said it would not review the vaccine because the company is partly owned by U.S.-Swiss tobacco company Philip Morris, health experts say.
Medicago’s vaccine on February 24 became the world’s first plant-based shot approved against COVID-19 after Health Canada cleared Covifenz for use in adults.
Dr. Reddy’s Laboratories Ltd. along with the company’s subsidiaries announced that Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules, was approved by Health Canada and launched in the Canadian market.
The U.S. Food and Drug Administration on May 19 authorized storage of Pfizer Inc. and German partner BioNTech SE’s Covid-19 vaccine at standard refrigerator temperatures for up to one month, in an effort to make the vaccine more widely available.
AstraZeneca Defends Covid-19 Vaccine with Updated DataAstraZeneca, Biomedical Advanced Research and Development Authority (BARDA), Coronavirus Disease 2019 (COVID-19), Covid-19 Data, COVID-19 Vaccines, Data Safety Monitoring Board (DSMB), Health Canada, Hospitalized COVID-19 Patients, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Oxford University, Symptomatic COVID-19 Infections
AstraZeneca released primary analysis showing that the company’s AZD1222 vaccine demonstrated 76 percent efficacy against symptomatic Covid-19, 100 percent efficacy against severe or critical disease and hospitalizations, and 85 percent efficacy against symptomatic Covid-19 in people 65 years and older.
CytoDyn’s Vyrologix Shortens Hospital Stays, Improves Survival in Severe Covid-19CCR5 antagonists, Clinical Data, Clinical Trials, Covid-19 Data, COVID-19 Severe Complications, Cytokine Storm, FDA, Health Canada, Hospitalized COVID-19 Patients, Immune Response, Medical Journals, Medicines and Healthcare products Regulatory Agency (MHRA), Primary Endpoints, R&D
Newly announced findings from a Phase III trial conducted by CytoDyn indicate that the use of the late-stage biotechnology company’s CCR5 antagonist candidate Vyrologix (leronlimab) was safe and improved the survival rate in critically ill hospitalized patients with coronavirus disease 2019.
Health Canada on Dec. 9 approved the Covid-19 vaccine from Pfizer Inc. and BioNTech SE, clearing the way for shots to be delivered and administered across the country.
U.S. inches closer to vaccine approval, economic relief as pandemic rages onBioNTech, CNN, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Vaccines, Democrats, Emergency Use Authorization, FDA, Health Canada, National Health Service (NHS), Pfizer, Republicans, United States, World Health Organization
Economic relief and a vaccine drew nearer to reality to counter a coronavirus pandemic that has ravaged the U.S. economy and killed 286,487 people with year-end holiday gatherings expected to fuel another surge in infections.
Defying Skeptics, Pfizer and Moderna Gun for Global Covid-19 Vaccine ApprovalBioNTech, China, Clinical Trials, Covid-19 Data, COVID-19 Vaccines, Drug Distributors, Emergency Use Authorization, Europe, European Medicines Agency, FDA/Regulatory, Health Canada, McKesson, Medicines and Healthcare products Regulatory Agency (MHRA), Moderna, NPR, Oxford University, Oxford University’s Jenner Institute, Pfizer, Product Pipelines, R&D, Russia, SwissMedic, United Kingdom
If all things go well, the Pfizer-BioNTech Covid-19 vaccine will receive EUA from the U.S. Food and Drug Administration around December 10 or within a few days after, and the Moderna vaccine will receive EUA around December 17 or within a few days after.